06/26/25
Clinical trial results for treatment of non-proliferative diabetic retinopathy
Carl Regillo, MD, Director of the Retina Service of Wills Eye Hospital, commented on the clinical trial results of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema. According to Dr. Regillo, "An oral approach like danegaptide has the potential to fundamentally shift how we treat moderate-to-severe stages of diabetic eye disease, offering patients a much-needed and non-invasive treatment solution for the large group of patients with NPDR.”